Mina Shahkarami

MAJIC: A Phase III Trial of Acalabrutinib + Venetoclax versus Venetoclax + Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Christine E. Ryan, Matthew S. Davids, Richard Hermann et al. · Future Oncology · 2022 · 35 citations · Full text

Medicine, Hematology, Oncology +17

Effect of Telephone Follow‐up on the Physical Well‐Being Dimension of Quality of Life in Patients with Cancer

Johnny Beney, Emily Beth Devine, Valby Chow et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2002 · 20 citations

Pharmacy, Oncology, Cancer Survivorship Care +15

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Matthew S. Davids, Jeff P. Sharman, Paolo Ghia et al. · Blood Advances · 2024 · 17 citations · Full text

Medicine, Oncology, Pharmacology +13

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Doǧan, Venkatraman Seshan et al. · Blood · 2024 · 11 citations · Full text

Medicine, Oncology, Pharmacology +11